SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000950142-17-000107
Filing Date
2017-01-12
Accepted
2017-01-12 17:16:25
Documents
3
Group Members
AISLING CAPITAL III, LPAISLING CAPITAL PARTNERS III LLCAISLING CAPITAL PARTNERS III, LPANDREW SCHIFFDENNIS PURCELLSTEVEN ELMS

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 eh1700166_13da1-loxo.htm SC 13D/A 158088
2 EXHIBIT 99.5 eh1700166_ex9905.htm EX-99.5 32135
3 EXHIBIT 99.6 eh1700166_ex9906.htm EX-99.6 34820
  Complete submission text file 0000950142-17-000107.txt   226707
Mailing Address 888 Seventh Avenue, 30th Fl New York NY 10106
Business Address 888 Seventh Avenue, 30th Fl New York NY 10106 212-651-6380
AISLING CAPITAL III LP (Filed by) CIK: 0001444717 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD CT 06901
Business Address 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD CT 06901 203-653-3880
Loxo Oncology, Inc. (Subject) CIK: 0001581720 (see all company filings)

IRS No.: 462996673 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88267 | Film No.: 17525926
SIC: 2834 Pharmaceutical Preparations